Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.

[1]  L. Ries,et al.  Ovarian cancer: Survival and treatment differences by age , 2010, Cancer.

[2]  D. Alberts,et al.  Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin–cyclophosphamide versus carboplatin–cyclophosphamide in stages III (suboptimal) and IV ovarian cancer: A southwest oncology group study , 2010, Cancer.

[3]  M. Brady,et al.  Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.

[4]  D. Katsaros,et al.  Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. , 2009, Critical reviews in oncology/hematology.

[5]  M. Birrer,et al.  Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. , 2009, Gynecologic oncology.

[6]  M. Xi,et al.  Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. , 2009, Gynecologic oncology.

[7]  Hang Lee,et al.  Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. , 2009, Gynecologic oncology.

[8]  C. Ballestín,et al.  Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[9]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[10]  D. Levine,et al.  Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. , 2007, Gynecologic oncology.

[11]  H. Gabra,et al.  Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients , 2007, Clinical Cancer Research.

[12]  Deborah Schrag,et al.  Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. , 2006, Journal of the National Cancer Institute.

[13]  B. Rosen,et al.  Who should operate on patients with ovarian cancer? An evidence-based review. , 2005, Gynecologic oncology.

[14]  L. Kolonel,et al.  Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. , 2005, American journal of epidemiology.

[15]  Jason D. Wright,et al.  Morbidity of Cytoreductive Surgery in the Elderly , 2003, American journal of obstetrics and gynecology.

[16]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Münstedt,et al.  Steroid hormone receptors and long term survival in invasive ovarian cancer , 2000, Cancer.

[18]  J. Aikins,et al.  Phase II study of mifepristone (RU486) in refractory ovarian cancer. , 2000, Gynecologic oncology.

[19]  M. Piver,et al.  Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. , 1998, American journal of clinical oncology.

[20]  P. Newcomb,et al.  Cancer treatment and age: patient perspectives. , 1993, Journal of the National Cancer Institute.

[21]  R. Barakat,et al.  Impact of age on survival of patients with ovarian cancer. , 1993, Gynecologic oncology.

[22]  K. Hatch,et al.  Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patients , 1991, Cancer.

[23]  B. Slotman,et al.  Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator , 1990, Cancer.

[24]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[25]  S. Pignata,et al.  Ovarian cancer in the elderly. , 2004, Critical reviews in oncology/hematology.

[26]  Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. , 2000, Gynecologic oncology.

[27]  R Yancik,et al.  Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. , 1993, Cancer.